Bausch Health Companies Inc. Stock News

LAVAL, QC, Oct. 28, 2026 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) today announced that its subsidiary, Bausch Health Americas, Inc., will issue an irrevocable notice of redemption dated as of October 29, 2026 pursuant to which it will redeem approximately $643 million of aggregate principal amount of its outstanding 8.500% Senior Notes due 2027, CUSIP Nos. 91911XAW4 and ...

LAVAL, QC, Oct. 28, 2026 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) today announced that its Board of Directors has authorized a share repurchase program under which the Company may repurchase its common shares ("Common Shares") for a total aggregate purchase price of up to US$50 million (the "Share Repurchase Program"). The primary objective of the Share Repurchase Progra...

Third Quarter Consolidated Revenues of $2.94 billion, up 10% on a Reported basis and 8% on an Organic1 basis over the prior year period GAAP Net Income Attributable to Bausch Health of $436 million and GAAP Net Income of $446 million GAAP Earnings per Diluted Share Attributable to Bausch Health of $1.15 compared to $0.48 in the prior year period; Adjusted Earnings per Diluted Share1 of $1.77 co...

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced its third-quarter 2026 financial results. “Our third-quarter performance reflects the strength and breadth of the business, with growth across all three segments and continued expansion in profitability,” said T...

LAVAL, QC, Oct. 12, 2026 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and its gastroenterology (GI) business, Salix Pharmaceuticals ("Salix"), announced results from a multicenter pilot study evaluating a standardized clinical pathway for cirrhosis management demonstrated improved adherence to evidence-based monitoring and treatment practices across community gastroenterolog...

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company, and its parent company, Bausch Health Companies Inc. (NYSE/TSX: BHC), today announced that Bausch + Lomb Board of Directors Chairman Thomas J. Appio has been appointed interim chief executive officer, effective immediately. Appio will continue to serve as CEO of Bausch Health whil...

Collaboration expands access to science-led, microbiome-friendly skincare solutions in Mexico and across new markets in EMEA, including launches in the Czech Republic, Slovakia, Ukraine, Bulgaria and Kazakhstan. LAVAL, QC, Sept.